In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Apyx Medical (APYX – Research Report). The company’s shares closed yesterday at $1.32.
Turkaly covers the Healthcare sector, focusing on stocks such as AxoGen, Lantheus, and Apyx Medical. According to TipRanks, Turkaly has an average return of -3.1% and a 38.66% success rate on recommended stocks.
Currently, the analyst consensus on Apyx Medical is a Moderate Buy with an average price target of $3.00.
APYX market cap is currently $64.09M and has a P/E ratio of -4.22.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apyx Medical (APYX) Company Description:
Apyx Medical Corp. operates as an energy-based medical technology company. It engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
